10 Odd Guidance On Roscovitine

These observations have been confirmed in several subsequent studies (Hedenus et?al, 2007; Henry et?al, 2007; Bastit et?al, 2008; Pedrazzoli et?al, 2008). Criteria for exclusion of co-existent IDA varied between these trials, and it is possible that significant numbers of patients included were in fact iron deficient, but the study by Hedenus et?al (2007) is of particular interest as it enrolled only patients with lymphoproliferative malignancies not receiving chemotherapy, and all patients had detectable bone marrow iron stores. In contrast, a recent study by Steensma et?al (2011) randomized patients with chemotherapy-associated anaemia to no iron, oral iron or intravenous iron plus darbepoietin: all had serum ferritin >20?��g/l and transferrin saturations http://en.wikipedia.org/wiki/Methisazone between the three groups. The mean pre-treatment ferritin levels in this http://www.selleckchem.com/products/Roscovitine.html study were higher than in the other studies, suggesting this population was less likely to have co-existent IDA, and the doses and scheduling of iron infusions were lower. Both these observations may partly explain the different results observed, but it is clear that further prospective studies, with better characterization of baseline iron stores are needed to define the role of intravenous iron supplementation in this setting. The ASH/ASCO guidelines (Rizzo et?al, 2010) recommend periodic monitoring of iron status in patients receiving treatment with http://www.selleckchem.com/products/bay-57-1293.html ESAs but fall short of recommending intravenous supplementation to augment responses. It is not yet known how intravenous iron might overcome the reticuloendothelial blockade on iron utilization thought to be fundamental to the pathogenesis of ACD, but it is possible that the infused iron may become bound directly to transferrin rather than being taken up by macrophages, and is thus available to the erythron. There are however no in vitro data to support this hypothesis. Safety issues also need to be considered when using intravenous iron, particularly as older preparations were associated with significant adverse events, including anaphylaxis (Auerbach & Ballard, 2010). Recent pharmacological developments have led to the release of several new iron formulations including low molecular weight iron dextran (Cosmofer?; Pharmacosmos, Holbaek, Denmark), iron sucrose (Venofer?; Vifor Pharma, Glattbrugg, Switzerland), ferric carboxymaltose (Ferinject?; Syner-Med Ltd, Purley, UK) and sodium ferric gluconate (Ferrlecit?; Watson Laboratories, Morristown, NJ, USA). In the trials above, no excess of adverse effects was observed with these newer intravenous iron preparations. One hypothesis for the hypoferraemia seen in ACD is that low iron levels might inhibit bacterial growth, as iron is essential for the growth and survival of intracellular bacteria, but there is no evidence to date that supplemental iron increases the risk of infections.